Abstract
Infliximab is approved for the induction and 1-year maintenance of remission in pediatric Crohn’s disease unresponsive to conventional therapy. Despite significant experience with the use of this agent in children and adolescents who have inflammatory bowel disease, many questions about its optimal use remain. Recent safety concerns raised debate over the common practice of using infliximab in combination with conventional immunomodulatory agents. Additionally, although regularly scheduled administration maintains remission more effectively than episodic therapy, it is not known whether all patients who start infliximab must continue it for maintenance. Some patients may be able to use infliximab for induction and another agent for maintenance. Finally, the optimal placement of infliximab in the algorithm for the medical treatment of pediatric inflammatory bowel disease remains an open question.
Similar content being viewed by others
References and Recommended Reading
Turunen P, Kolho KL, Auvinin A, et al.: Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm Bowel Dis 2006, 12:677–683.
Baldassano R, Ferry G, Griffiths A, et al.: Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002, 34:245–248.
Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255–260.
Markowitz J, Hyams J, Mack D, et al.: Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol 2006, 4:1124–1129.
Hyams J, Markowitz J, Lerer T, et al.: The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006, 3:1118–1123.
Day AS, Whitten KE, Sidler M, Lemberg DA: Systematic review: nutritional therapy in paediatric Crohn’s disease. Aliment Pharmacol Ther 2007, 27:293–307.
Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997, 92:204–211.
Cottone M, Camma C: Mesalamine and relapse prevention in Crohn’s disease. Gastroenterology 2000, 119:597.
Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119:895–902.
Kirschner B: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813–821.
Fegan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632.
Fegan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995, 332:330–331.
Uhlen S, Belbouab R, Narebski K, et al.: Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm Bowel Dis 2006, 12:1053–1057.
Turner D, Grossman AB, Rosh JR, et al.: Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 2007, 102:2804–2812.
Ten Hove T, van Montfrans C, Peppelenbosch MP, et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2003, 50:206–211.
Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641–1657.
Derkx B, Taminiau J, Radema S, et al.: Tumor-necrosis-factor antibody treatment in Crohn’s disease. Lancet 1993, 342:173–174.
De Ridder L, Benninga MA, Taminiau J, et al.: Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 45:3–14.
Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:934–936.
Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet 2002, 359:1541–1549.
Rutgeerts P, Van Assche G, Vermeire S: Review article: infliximab therapy for inflammatory bowel disease—seven years on. Aliment Pharmacol Ther 2006, 23:451–463.
Hyams J, Crandall W, Kugathasan S, et al.: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007, 132:863–873.
Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476.
Remicade (infliximab) for IV injection (package insert). Malvern, PA: Centocor; 2007.
Rutgeerts P, Feagan BG, Lichtenstein GR: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.
Kevans D, Keegan D, Mulcahy HE, O’Donoghue DP: Infliximab therapy in Crohn’s disease: a pragmatic approach? Aliment Pharmacol Ther 2006, 24:351–359.
Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid dependant Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054–1061.
Feldman T, Youssef NN, Irizarry R, Rosh JR: Infliximab as an induction agent versus ongoing maintenance therapy in mild-moderate pediatric Crohn’s disease [abstract]. Gastroenterology 2007, 2069:A444.
Chaudhary R, Butler M, Playford R, et al.: Combination immunomodulatory therapy with infliximab increases mononuclear cell apoptosis in-vitro compared to infliximab alone. Gastroenterology 2005:A149.
Roblin X, Serre-Debeauvais F, Phelip JM, et al.: Drug interaction between infliximab and azathioprine in patients with Crohn’s disease. Aliment Pharmacol Ther 2003, 18:917–925.
Klotz U, Teml A, Schwab M: Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007, 46:645–660.
Hanauer SB, Wager CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:542–543.
Rutgeerts P, Feagan BG, Lichtenstein GR: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.
Faffell RJ, Alsahli M, Jeen T, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924.
Vermeire S, Noman M, Van Assche GV, et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007, 56:1226–1231.
Van Assche G, Paintaud G, Magdelaine C, et al.: Concomitant immunosuppression does not impact on the outcome of maintenance infliximab therapy in Crohn’s disease [abstract]. Gastroenterology 2007, 132:A103.
Kugathasan S, Ehlert R, Stephens MC, et al.: Immunomodulators are not required to maintain efficacy with infliximab in pediatric inflammatory bowel disease [abstract]. Gastroenterology 2007, 132:A443.
Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: The CHARM trial. Gastroenterology 2007, 132:52–65.
Sandborn WJ, Rutgeerts P, Enns SB, et al.: Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007, 146:829–838.
Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma in among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121–1125.
Khanna D, McMahon M, Furst DE: Safety of tumor necrosis factor-alpha antagonists. Drug Saf 2004, 27:307–324.
Mackey AC, Green L, Liang LC, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265–267.
Rosh JR, Gross T, Mamula P, et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn disease: a cautionary tale? Inflamm Bowel Dis 2007, 13:1024–1030.
Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005, 54:237–241.
Kugathasan S, Werlin SL, Martinez A, et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000, 95:3189–3194.
D’Haens G, Baert F, van Assche G, et al.: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008, 371:660–667.
Romeo E, Viola F, De Angelis G, et al.: Infliximab as a first choice therapy in children with newly diagnosed Crohn’s disease (CD) promotes long-term sustained remission and alters the course of the disease. Gastroenterology 2006, 130:A142.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosh, J.R. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 10, 302–307 (2008). https://doi.org/10.1007/s11894-008-0060-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-008-0060-5